Product Details
Alternative Name: | ABCB1, CD243, P-glycoprotein 1 |
|
Clone: | C219 |
|
Host: | Mouse |
|
Isotype: | IgG1 |
|
Immunogen: | SDS-solubilized plasma membranes of an MDR (multidrug resistant) Chinese hamster ovary (CHO) cell line and a human cell line. |
|
UniProt ID: | P08183 |
|
Species reactivity: | Human, Mouse, Rat Dog, Primate
|
|
Specificity: | Recognizes an internal, highly conserved amino acid sequence (VQEALD and VQAALD) found in both protein isoforms, P-glycoprotein and MDR3 P-glycoprotein. |
|
Crossreactivity: | Cross-reacts with a ~200kDa protein which migrates in the same position as myosin and with C-erbB2 protein (p185c-erbB2). |
|
Applications: | ICC, IHC (FS), IHC (PS), IP
|
|
Recommended Dilutions/Conditions: | Immunohistochemistry (paraffin sections): - For optimal staining, the sections should be pretreated with an antigen unmasking solution. - The antibody may be diluted to ≥1:25 for biotin based detection systems. - For optimal staining, the primary antibody should be incubated 60 minutes at room temperature.
Western Blot (1:50-1:100)
Suggested dilutions/conditions may not be available for all applications. Optimal conditions must be determined individually for each application. |
|
Application Notes: | Flow Cytometry: cell permeabilization required.
Detects bands of ~170kDa (MDR1 P-glycoprotein) and of ~140kDa (MDR3 P-glycoprotein) by Western blot.
Cited applications include ELISA, IF, FC, and WB |
|
Positive Control: | Cell lines: Appropriate drug-sensitive parental cell lines and their multidrug resistant derivatives prepared by the same methods as the test specimens can be used as control materials. Tissue: Human liver (positive staining detected along luminal surfaces of bile canaliculi) or human colon (positive staining localized to luminal surface of secretory epithelium) are recommended. |
|
Formulation: | Liquid. In 0.01M PBS containing 1% BSA and 0.1% sodium azide. |
|
Handling: | Keep at +4°C. Do not freeze. |
|
Shipping: | Blue Ice |
|
Short Term Storage: | +4°C |
|
Long Term Storage: | +4°C |
|
Regulatory Status: | RUO - Research Use Only |
|
Product Literature References
Dependence of ABCB1 transporter expression and function on distinct sphingolipids generated by ceramide synthases-2 and -6 in chemoresistant renal cancer: W.K. Lee, et al.; Int. J. Mol. Med.
31, 101492 (2022),
Abstract;
Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents: J. Lee, et al.; Pharmaceutics
13, 559 (2021),
Abstract;
Quantification of P-Glycoprotein in the Gastrointestinal Tract of Humans and Rodents: Methodology, Gut Region, Sex, and Species Matter: Y. Mai, et al.; Mol. Pharm.
18, 1895 (2021),
Abstract;
Microtubule-targeting anticancer drug eribulin induces drug efflux transporter P-glycoprotein: T. Nabekura, et al.; Biochem. Biophys. Rep.
21, 100727 (2020),
Application(s): Western Blot,
Abstract;
Full Text
Optimization of an Oral Mucosa in vitro Model Based on Cell Line TR146: G.C. Lin, et al.; Tissue Barriers
21, 1748459 (2020),
Abstract;
Impact of Viral Inflammation on the Expression of Renal Drug Transporters in Pregnant Rats: N. Karimian Pour, et al.; Pharmaceutics
11, 624 (2019),
Abstract;
Full Text
Class III β-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line: K. Yahiro, et al.; Anal. Cell. Pathol. (Amst.)
2018, 8987568 (2018),
Application(s): WB in human leiomysarcoma cell line SK-LMS-2,
Abstract;
Full Text
Endotoxin Modulates the Expression of Renal Drug Transporters in HIV-1 Transgenic Rats: N. Karimian Pour, et al.; J. Pharm. Pharm. Sci.
21, 117s (2018),
Abstract;
Expression of genes and proteins of multidrug resistance in gastric cancer cells treated with resveratrol: K. Mieszala, et al.; Oncol. Lett.
15, 5825 (2018),
Abstract;
Full Text
Inhibition of sirtuins 1 and 2 impairs cell survival and migration and modulates the expression of P-glycoprotein and MRP3 in hepatocellular carcinoma cell lines: M.P. Ceballos, et al.; Toxicol. Lett.
289, 63 (2018),
Abstract;
MicroRNA-655-3p regulates Echinacea purpureamediated activation of ABCG2: C. Awortwe, et al.; Xenobiotica
48, 1050 (2018),
Abstract;
Impact of Endotoxin on the Expression of Drug Transporters in the Placenta of HIV-1 Transgenic (HIV-Tg) Rats: R.H. Ghoneim, et al.; Eur. J. Pharm. Sci.
102, 94 (2017),
Abstract;
Full Text
Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines: R. Januchowski, et al.; J. Ovarian Res.
9, 65 (2016),
Application(s): Immunofluorescence analysis, human ovarian carcinoma cell line A2780,
Abstract;
Full Text
Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrier: H. Chapy, et al.; Br. J. Pharmacol.
173, 497 (2016),
Abstract;
Full Text
Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines: R. Januchowski, et al.; Int. J. Biochem. Cell Biol.
78, 248 (2016),
Application(s): Immunofluorescence,
Abstract;
Leukemia Inhibitory Factor Enhances Endogenous Cardiomyocyte Regeneration after Myocardial Infarction: M. Kanda, et al.; PLoS One
11, e0156562 (2016),
Application(s): Western blot,
Abstract;
Full Text
Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines: K. Wojtowicz, et al.; Biomed. Pharmacother.
74, 49 (2015),
Application(s): Western blot, Immunocytochemistry,
Abstract;
Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure: D. Imrichova, et al.; Eur. J. Pharm. Sci.
77, 29 (2015),
Application(s): Western Blot,
Abstract;
Plasma membrane phospholipase A2 controls hepatocellular fatty acid uptake and is responsive to pharmacological modulation: implications for nonalcoholic steatohepatitis: W. Stremmel, et al.; FASEB J.
28, 3159 (2014),
Abstract;
St. John's Wort reduces beta-amyloid accumulation in a double transgenic Alzheimer's disease mouse model-role of P-glycoprotein: A. Brenn, et al.; Brain Pathol.
24, 18 (2014),
Application(s): IHC using mouse brain tissue,
Abstract;
Full Text
Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood–brain barrier permeability: F.E. O'Brien, et al.; Int. J. Neuropsychopharmacol.
16, 2259 (2013),
Abstract;
P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study: M. Feldmann, et al.; Lancet Neurol.
12, 777 (2013),
Application(s): IHC using brain tissue,
Abstract;
Beta-Amyloid Downregulates MDR1-P-Glycoprotein (Abcb1) Expression at the Blood-Brain Barrier in Mice: A. Brenn, et al.; Int. J. Alzheimers Dis.
2011, 690121 (2011),
Application(s): IHC using mouse brain tissue,
Abstract;
Full Text
Effect of Variations in the Amounts of P-Glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the Human Small Intestine on PBPK Models for Predicting Intestinal First Pass: A. Bruyere, et al.; Mol. Pharm.
7, 1596 (2010),
Abstract;
Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin: S. Borska, et al.; Molecules
15, 857 (2010),
Abstract;
Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier: B. Poller, et al.; Cell. Mol. Neurobiol.
30, 63 (2010),
Abstract;
The P-glycoprotein inhibitor GF120918 modulates Ca2+-dependent processes and lipid metabolism in Toxoplasma gondii: I. Bottova, et al.; PLOS ONE
5, e10062 (2010),
Abstract;
Expression and Localization of P-glycoprotein in Human Heart: Effects of Cardiomyopathy: K. Meissner, et al.; J. Histochem. Cytochem.
50, 1351 (2002),
Application(s): Immunostaining,
Abstract;
Full Text
Characterization of multidrug transporters in a normal renal tubular cell line resistant to doxorubicin. Multidrug transporters in the LLC-PK(1) cell line and its resistant counterpart: G. Decorti, et al.; Biochem. Pharmacol.
61, 61 (2001),
Abstract;
Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone: R. Yumoto, et al.; Drug. Metab. Dispos.
29, 145 (2001),
Abstract;
Full Text
Activation of the human P-glycoprotein ATPase by trypsin: S.L. Nuti, et al.; Biochemistry
39, 3424 (2000),
Abstract;
Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart: A. Rosati, et al.; Anticancer Res.
20, 3403 (2000),
Abstract;
Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response: I.O. Ng, et al.; Am. J. Clin. Pathol.
113, 355 (2000),
Abstract;
Nucleotide-induced conformational changes in P-glycoprotein and in nucleotide binding site mutants monitored by trypsin sensitivity: M. Julien & P. Gros; Biochemistry
39, 4559 (2000),
Abstract;
P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries: M. Demeule, et al.; FEBS Lett.
466, 219 (2000),
Abstract;
Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies: G.L. Scheffer, et al.; Cancer Res.
60, 5269 (2000),
Abstract;
Full Text
Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis: F. Thevenod, et al.; J. Biol. Chem.
275, 1887 (2000),
Abstract;
Full Text
A multidrug-resistant breast cancer cell line induced by weekly exposure to doxorubicin: S.M. Hahn, et al.; Int. J. Oncol.
14, 273 (1999),
Abstract;
Antibody C219 recognizes an alpha-helical epitope on P-glycoprotein: J.M. van Den Elsen, et al.; PNAS
96, 13679 (1999),
Abstract;
Full Text
Characterization of cyclosporin A transport in cultured rabbit corneal epithelial cells: P-glycoprotein transport activity and binding to cyclophilin: K. Kawazu, et al.; Invest. Ophtalmol. Vis. Sci.
40, 1738 (1999),
Abstract;
Clinical significance of P-glycoprotein (P-gp) expression in childhood acute lymphoblastic leukemia. Results of a 6-year prospective study: C. Dhooge & B. De Moerloose; Adv. Exp. Med. Biol.
457, 11 (1999),
Abstract;
Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival: H. Yokoyama, et al.; Surg. Today
29, 1141 (1999),
Abstract;
Interferon α2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype: M.H. Frank & S. Pomer; J. Cancer. Res. Clin. Oncol.
125, 117 (1999),
Abstract;
Kinetics of doxorubicin handling in the LLC-PK1 kidney epithelial cell line is mediated by both vesicle formation and P-glycoprotein drug transport: E. Crivellato, et al.; Histochem. J.
31, 635 (1999),
Abstract;
Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells: H. Wada, et al.; Exp. Hematol.
27, 99 (1999),
Abstract;
The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme: R. Durmaz, et al.; Clin. Neurol. Neurosurg.
101, 238 (1999),
Abstract;
Transport of doxorubicin in mast cell granules and the effect of the calcium antagonist verapamil: L. Candussio, et al.; Anticancer Res.
19, 1101 (1999),
Abstract;
P-glycoprotein expression and prognostic value in acute myeloid leukemia: L. Senent, et al.; Haematologica
83, 783 (1998),
Abstract;
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations: W.T. Beck, et al.; Cancer Res.
56, 3010 (1996),
Abstract;
MRP and MDR1 gene expression in primary breast carcinomas: M. Filipits, et al.; Clin. Cancer Res.
2, 1231 (1996),
Abstract;
New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues: K. Toth et al.; Am. J. Pathol.
144, 227 (1994),
Abstract;
Comparison of an immunoperoxidase "sandwich" staining method and western blot detection of P-glycoprotein in human cell lines and sarcomas: K. Toth, et al.; Am. J. Pathol.
140, 1009 (1992),
Abstract;
Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies: A.H. Schinkel, et al.; Cancer Res.
51, 2628 (1991),
Abstract;
A sensitive method for immunocytochemical detection of P-glycoprotein in multidrug-resistant human ovarian carcinoma cell lines: H.S. Chan, et al.; Lab. Invest.
59, 870 (1988),
Abstract;
Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies: N. Kartner, et al.; Nature
316, 820 (1985),
Abstract;